NASDAQ : TBPH
Theravance Biopharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 17.03 USD (At close: Sep 23, 2026) · Market cap 884.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 884.18M |
| Enterprise Value | 535.09M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 51.92M |
| Shares Outstanding | 51.92M |
| Shares Change (YoY) | +3.94% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 6.22% |
| Owned by Institutions (%) | 49.35% |
| Float | 25.87M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 16.30 |
| Forward PE | 8.41 |
| PS Ratio | 8.48 |
| Forward PS | 9.28 |
| PB Ratio | 3.05 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | 16.45 |
| P/OCF Ratio | 16.45 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 9.94 |
| EV / Sales | 5.13 |
| EV / EBITDA | 48.20 |
| EV / EBIT | 56.03 |
| EV / FCF | 9.96 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.54 |
| Quick Ratio | 13.26 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 3.47 |
| Debt / FCF | 0.72 |
| Interest Coverage | 8.27 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 20.91% |
| Return on Assets (ROA) | 1.33% |
| Return on Invested Capital (ROIC) | -3.66% |
| Return on Capital Employed (ROCE) | 2.18% |
| Weighted Average Cost of Capital (WACC) | 5.48% |
| Revenue Per Employee | $1.16M |
| Profits Per Employee | $597,867 |
| Employee Count | 90 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 5.11M |
| Effective Tax Rate | 8.67% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +21.04% |
| 50-Day Moving Average | 16.96 |
| 200-Day Moving Average | 17.18 |
| Relative Strength Index (RSI) | 53.24 |
| Average Volume (20 Days) | 1,176,771 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.62M |
| Short Previous Month | 1.71M |
| Short % of Shares Out | 3.12% |
| Short % of Float | 6.26% |
| Short Ratio (days to cover) | 3.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 104.31M |
| Gross Profit | 78.30M |
| Operating Income | 9.55M |
| Pretax Income | 58.92M |
| Net Income | 53.81M |
| EBITDA | 11.10M |
| EBIT | 9.55M |
| Earnings Per Share (EPS) | $1.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 387.66M |
| Total Debt | 38.57M |
| Net Cash | 349.09M |
| Net Cash Per Share | $6.72 |
| Equity (Book Value) | 289.71M |
| Book Value Per Share | 5.58 |
| Working Capital | 385.90M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 53.74M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 1.55M |
| Net Borrowing | n/a |
| Free Cash Flow | 53.73M |
| FCF Per Share | $1.03 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.06% |
| Operating Margin | 9.16% |
| Pretax Margin | 56.48% |
| Profit Margin | 51.58% |
| EBITDA Margin | 10.64% |
| EBIT Margin | 9.16% |
| FCF Margin | 51.51% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.94% |
| Shareholder Yield | -3.94% |
| Earnings Yield | 6.09% |
| FCF Yield | 6.08% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.67 |
| Price Target Difference | 3.76% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | -6.02% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.36 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |